SCHEMBL5372745

SCHEMBL5372745

O=C(O)c1ccc(NC(=S)NN=Cc2ccc(-c3ccccc3)cc2O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 2/20 0.57
ALDH1A1 P00352 8/20 0.53
RAB9A P51151 7/20 0.53
KMT2A Q03164 6/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
TDP1 Q9NUW8 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
PKM P14618 2/20 0.53
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
HDAC8 Q9BY41 1/20 0.51
MAPT P10636 8/20 0.48
GAA P10253 7/20 0.48
KDM4E B2RXH2 7/20 0.48
NPC1 O15118 7/20 0.48
MEN1 O00255 5/20 0.48
L3MBTL1 Q9Y468 4/20 0.47
LMNA P02545 2/20 0.47
HPGD P15428 2/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5372739 1.00 SIRT1 (0.57) SIRT1ALDH1A1RAB9AKMT2ASMN1; SMN2
SCHEMBL5366765 0.89 MAPT (0.62) SIRT1ALDH1A1RAB9AKMT2ASMN1; SMN2
SCHEMBL5366770 0.89 MAPT (0.62) SIRT1ALDH1A1RAB9AKMT2ASMN1; SMN2
SCHEMBL5373019 0.82 NCOA1 (0.55) ALDH1A1RAB9AKMT2ASMN1; SMN2TDP1
SCHEMBL5373013 0.82 NCOA1 (0.55) ALDH1A1RAB9AKMT2ASMN1; SMN2TDP1
SCHEMBL5361204 0.81 MEN1 (0.54) ALDH1A1RAB9AKMT2ASMN1; SMN2TDP1
SCHEMBL5361197 0.81 MEN1 (0.54) ALDH1A1RAB9AKMT2ASMN1; SMN2TDP1
SCHEMBL5364181 0.79 MAPT (0.54) SIRT1ALDH1A1RAB9AKMT2ASMN1; SMN2
SCHEMBL5364183 0.79 MAPT (0.54) SIRT1ALDH1A1RAB9AKMT2ASMN1; SMN2
SCHEMBL5367508 0.79 HDAC8 (0.52) ALDH1A1RAB9AKMT2ASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP claimed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP claimed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK SIRT1 3379/4885ALDH1A1 1889/4885RAB9A 3652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.